相关实验视频

Updated: May 24, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

944

双ITK/JAK3小分子共价抑制剂ATI-2138的表征

Aparna Kaul1, Heidi Hope1, Canxin Xu1

  • 1Confluence Discovery Technologies, St. Louis, Missouri.

The Journal of pharmacology and experimental therapeutics
|March 1, 2025
PubMed
概括

阿克拉里斯治疗公司 (ATI) - 2138是一种新型共价抑制剂,有效向介素-2-诱导性T细胞激酶 (ITK) 和Janus激酶3 (JAK3). 这种药物在临床前模型中显示出疾病修饰作用,并且在人类自身免疫性疾病中具有良好的安全性.

关键词:
这是自身免疫性疾病.一个共价的共价物.介素-2诱导性T细胞激酶.亚努斯酶 3 亚努斯酶 3 亚努斯酶基因酶激酶的使用方法

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.1K

相关概念视频

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.6K